# A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Source: https://onco.cc/trials/nct05999994/  
OnCo record `nct05999994` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib in advanced solid tumours, run by Eli Lilly and Company, now recruiting.

## Summary

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer is a phase 2 interventional study registered as NCT05999994 by Eli Lilly and Company, with 105 participants planned, started 2020-01-22 and due to reach its primary completion in 2027-05. Interventions recorded: Ramucirumab, Cyclophosphamide, Vinorelbine, Gemcitabine, Docetaxel and Abemaciclib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05999994
- Phase: 2
- Setting: CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research
- Sponsor: Eli Lilly and Company
- Enrolled: 105

## Sources

- ClinicalTrials.gov NCT05999994: https://clinicaltrials.gov/study/NCT05999994

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/), [Vinorelbine](https://onco.cc/drugs/vinorelbine/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)

---
JSON: https://onco.cc/api/v1/entities/nct05999994.json